INDIVIDUALIZED MANAGEMENT STRATEGIES FOR VERY SEVERE HYPERTRIGLYCERIDEMIA

Le résumé fourni par la source

INTRODUCTION/BACKGROUNDVery severe hypertriglyceridemia (HTG) is defined by the Endocrine Society as a serum triglyceride concentration ≥22.6 mmol/L. Management typically involves dietary modification, pharmacotherapy such as fibrates combined with statins, insulin therapy, and plasmapheresis in select cases. We report two cases of non-familial very severe HTG secondary to poorly controlled type 2 diabetes mellitus, each managed using different therapeutic strategies. CASECase 1: A 23-year-old female with type 2 diabetes mellitus and class I obesity (BMI 29.3 kg/m²) presented with diabetic ketoacidosis and acute pancreatitis. She had a history of poor adherence to insulin therapy. Her serum triglyceride level was markedly elevated at 64 mmol/L. She was treated with a fixed-rate intravenous insulin infusion (0.1 units/kg/hour) and kept on nothing per orem, resulting in a significant reduction of triglyceride levels to 2.5 mmol/L within three days. Case 2: An 83-year-old female with type 2 diabetes mellitus, stage 4 chronic kidney disease, hypertension, neurocognitive disorder and osteoporosis who was incidentally found to have severe HTG (25.6 mmol/L) during routine screening. Despite being asymptomatic, she was started on a variable-rate intravenous insulin infusion to reduce the risk of pancreatitis. Her triglyceride levels decreased to 16.8 mmol/L but then plateaued. Insulin was discontinued, and a low-carbohydrate, low-fat diet with intermittent fasting (from lunch until the next day’s breakfast) was initiated. This led to a reduction in her triglyceride level to 9.01 mmol/L within three days. Both patients were discharged with premixed insulin, rosuvastatin, omega-3 fatty acid supplementation and additional fenofibrate for Case 1 only, as Case 2 has CKD stage 4. CONCLUSIONThese cases highlight the importance of individualized treatment strategies in managing very severe non-familial HTG. While insulin infusion and dietary interventions were effective in both patients, the choice of therapy should be guided by clinical context.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.